¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"immunologic enhancement"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • enhancement medium
    Áõ°­¹èÁö
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • rim enhancement
    Å×Áõ°­
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • enhancement
    Áõ°­, ÁõÁø
  • edge enhancement
    °¡ÀåÀÚ¸®Áõ°­
  • enhancement medium
    Áõ°­¹èÁö
  • inflow enhancement
    À¯ÀÔÁõ°­
  • magnetic susceptibility proton relaxation enhancement
    ÀÚ±âÈ­À²¾ç¼ºÀÚÀÌ¿ÏÁõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÁ¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³ÀûÁ¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • periventricular enhancement
    ³ú½ÇÁÖÀ§Á¶¿µÁõ°­
  • rim enhancement
    Å×Áõ°­
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • thermal enhancement ratio
    ¿Â¿­Áõ°¨ºñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic function
    ¸é¿ª±â´É.
  • immunologic infertilily
    ¸é¿ªÇÐÀûºÒÀÓ
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • immunologic intervention
    ¸é¿ª(ÇÐÀû)Á¶Á¤.
  • immunologic memory
    ¸é¿ª±â¾ï.
  • immunologic reaction
    ¸é¿ª¹ÝÀÀ
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ.
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunologic surveillance
    ¸é¿ª°¨½Ã(±â±¸).
  • immunologic system
    ¸é¿ª°è.
  • immunologic technique
    ¸é¿ªÇÐÀû±â¼ú
  • immunologic test
    ¸é¿ª°Ë»ç
  • immunologic thrombocytopenic purpura
    ¸é¿ª¼º Ç÷¼ÒÆÇ°¨¼Ò¼º ÀÚ¹Ý
  • immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • immunologic tolerance
    ¸é¿ª°ü¿ë(¡­Î°é»)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic surveillance
    ¸é¿ª°¨½Ã(±â±¸).
  • immunologic system
    ¸é¿ª°è.
  • immunologic technique
    ¸é¿ªÇÐÀû±â¼ú
  • immunologic test
    ¸é¿ª°Ë»ç
  • immunologic thrombocytopenic purpura
    ¸é¿ª¼º Ç÷¼ÒÆÇ°¨¼Ò¼º ÀÚ¹Ý
  • immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • immunologic tolerance
    ¸é¿ª°ü¿ë(¡­Î°é»)
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªÇÐÀû ºÒÀÀ»óÅÂ(ÝÕëëßÒ÷¾)
  • acoustic enhancement
    À½Çâ Áõ°­
  • contrast enhancement
    Á¶¿µ Áõ°­
  • contrast enhancement ratio
    Á¶¿µ Áõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­ ½ºÄµ
  • dense enhancement
    °­ÇÑ Á¶¿µÁõ°­
  • edge enhancement
    º¯¿¬ Áõ°­
  • enhancement
    Áõ°­
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • posterior echo enhancement
    ÈĹ濡ÄÚÁõ°­, ÈĹæ¸Þ¾Æ¸®Áõ°­
  • proton relaxation enhancement
    ¾çÀÚÀÌ¿ÏÁõ°­
  • rapid acquisition with relaxation enhancement [=RARE]
    ÀÌ¿ÏÁõ°­±Þ¼Óȹµæ
  • rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • ring enhancement
    ȯ»óÁ¶¿µÁõ°­
  • sonic enhancement
    À½ÆÄÁõ°­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DEPT distortionless enhancement by polarization transfer
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
FRE Fischer rat embryo; flow-related enhancement
LME left mediolateral episiotomy; leukocyte migration enhancement
MEF maximal expiratory flow; middle ear fluid; midexpiratory flow; migration enhancement factor; mouse e...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MET Motivational Enhancement Therapy
NOESY Nuclear Over-hauser enhancement spectroscopy
NOE Nuclear Overhauser Enhancement
OER Oxygen Enhancement Ratio
RARE Rapid Acquisition with Relaxation Enhancement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µ Áõ°­
  • peripheral rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • ring enhancement
    ȯ»ó Á¶¿µ Áõ°­
  • sonic enhancement
    À½ÆÄ Áõ°­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
cytotoxicity, immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
(12 Dec 1998)
cytotoxicity tests, immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement.
(12 Dec 1998)
suppressor factors, immunologic Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory.
(12 Dec 1998)
desensitization, immunologic Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
immunologic <immunology> Pertaining to immunology.
(18 Nov 1997)
immunologic and biological factors A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity.
(12 Dec 1998)
immunologic capping The process by which lymphoid cell surface immunoglobulin receptors, when exposed to bivalent anti-ig antibodies, collect in patches and form a cap at one pole of the cell. The caps may then be endocytosed or shed into the environment in the form of antigen-antibody complexes. Capping has also been induced by lectins and antigens.
(12 Dec 1998)
immunologic deficiency syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
(12 Dec 1998)
immunologic diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated or both.
(12 Dec 1998)
immunologic factors Biologically active substances whose activities affect or play a role in the functioning of the immune system.
(12 Dec 1998)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
immunologic memory <immunology> The ability to rapidly produce large quantities of specific immune cells after subsequent exposure to a previously encountered antigen.
(09 Oct 1997)
immunologic pregnancy test A general term for test's for detection of increased human chorionic gonadotropin in plasma or urine by immunologic techniques including latex particle agglutination, haemagglutination inhibition, radioimmunoassay, and radioreceptor assays.
(05 Mar 2000)
immunologic surveillance The theory that T-cells monitor cell surfaces and detect structural changes in the plasma membrane and/or surface antigens of virally or neoplastically transformed cells.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á